Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020; 395: 817‑ 827.

https://doi.org/10.1016/S0140-6736(20)30165-3 DOI: https://doi.org/10.1016/S0140-6736(20)30165-3

Wekking D, Lambertini M, Dessì M, Denaro N, Bardanzellu F, Garrone O, et al. CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. Semin Oncol 2023; 50: 131-139.

https://doi.org/10.1053/j.seminoncol.2024.01.002 DOI: https://doi.org/10.1053/j.seminoncol.2024.01.002

Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann Dermatol Vénéréologie 2023; 150: 208‑ 212.

https://doi.org/10.1016/j.annder.2022.11.013 DOI: https://doi.org/10.1016/j.annder.2022.11.013

Widmer S, Grossman M. Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: A case report. Am J Emerg Med 2018; 36: 1325.e3-1325.e4.

https://doi.org/10.1016/j.ajem.2018.04.019 DOI: https://doi.org/10.1016/j.ajem.2018.04.019

Kowalczyk A, Radecka B. Stevens-Johnson syndrome in breast cancer patient treated with ribociclib. Oncol Clin Pract 2023; 19: 59‑62.

https://doi.org/10.5603/OCP.2022.0004 DOI: https://doi.org/10.5603/OCP.2022.0004

Vrana E, Mylona S, Bobos M, Kontovinis L, Papazisis K. Ribociclib and palbociclib-induced erythema multiforme: a case report. Oxf Med Case Rep 2022; 2022: omac116.

https://doi.org/10.1093/omcr/omac116 DOI: https://doi.org/10.1093/omcr/omac116

López-Gómez V, Yarza R, Muñoz-González H, Revilla E, Enrech S, González-Valle O, et al. Ribociclib-related Stevens-Johnson syndrome: oncologic awareness, case report, and lit-erature review. J Breast Cancer 2019; 22: 661-666.

https://doi.org/10.4048/jbc.2019.22.e44 DOI: https://doi.org/10.4048/jbc.2019.22.e44

Bozkaya Y, Ay B. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer. Breast J 2020; 26: 773‑774.

https://doi.org/10.1111/tbj.13570 DOI: https://doi.org/10.1111/tbj.13570

Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, et al. Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol 2022; 23: 247‑255.

https://doi.org/10.1007/s40257-021-00645-0 DOI: https://doi.org/10.1007/s40257-021-00645-0

Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, et al. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep 2018; 4: 452‑454.

https://doi.org/10.1016/j.jdcr.2017.12.015 DOI: https://doi.org/10.1016/j.jdcr.2017.12.015

Ingen-Housz-Oro S, Duong TA, Bensaid B, Bellon N, De Prost N, et al. Epidermal necro-lysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis 2018; 13: 56.

https://doi.org/10.1186/s13023-018-0793-7 DOI: https://doi.org/10.1186/s13023-018-0793-7

Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther 2020; 10: 221‑229.

https://doi.org/10.1007/s13555-020-00353-3 DOI: https://doi.org/10.1007/s13555-020-00353-3

Kridin K, Brüggen MC, Chua SL, Bygum A, Walsh S, Nägeli MC, et al. Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European multicenter study. JAMA Dermatol 2021; 157: 1182-1190.

https://doi.org/10.1001/jamadermatol.2021.3154 DOI: https://doi.org/10.1001/jamadermatol.2021.3154

Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 2018; 128: 985‑996.

https://doi.org/10.1172/JCI93349 DOI: https://doi.org/10.1172/JCI93349